Key result
Bevacizumab lowers right ventricular pressure by ~6 mmHg versus saline in pulmonary hypertension.
Why the study?
The molecular differences in lung proteome profiles between monocrotaline and chronic hypoxia models of pulmonary arterial hypertension were not fully characterized.
Absolute Event Rate: 32.3% vs 37.8%
p-value: p=0.01
Bevacizumab may lower RV pressure in hypoxia PH rats; hypothesis-generating for VEGF targeting and should not change practice.
We studied the lung proteome changes in two widely used models of pulmonary arterial hypertension (PAH): monocrotaline (MCT) injection and chronic hypoxia (CH); untreated rats were used as controls (n = 6/group). After 28 days, invasive right ventricular systolic pressure (RVSP) was measured. Lungs were immunostained for alpha-smooth muscle actin (alphaSMA). 2-DE (n = 4/group) followed by nano-LC-MS/MS was applied for protein identification. Western blotting was used additionally if possible. RVSP was significantly increased in MCT- and CH-rats (MCT 62.5 +/- 4.4 mmHg, CH 62.2 +/- 4.1 mmHg, control 25.0 +/- 1.7 mmHg, p<0.001). This was associated with an increase of alphaSMA positive vessels. In both groups, there was a significantly increased expression of proteins associated with the contractile apparatus (diphosphoHsp27 (p<0.001), Septin2 (p<0.001), F-actin capping protein (p<0.01), and tropomyosin beta (p<0.02)). In CH, proteins of the nitric oxide (Hsc70; p = 0.002), carbon monoxide (biliverdin reductase; p = 0.005), and vascular endothelial growth factor (VEGF) pathway (annexin 3; p<0.001) were significantly increased. In MCT, proteins involved in serotonin synthesis (14-3-3; p = 0.02), the enhanced unfolded protein response (ERp57; p = 0.02), and intracellular chloride channels (CLIC 1; p = 0.002) were significantly elevated. Therefore, MCT- and CH-induced vasoconstriction and remodeling seemed to be mediated via different signaling pathways. These differences should be considered in future studies using either PAH model.
No takes yet. Share an insight, caveat, or question.
A 2007 study studied Pulmonary arterial hypertension (n=24). Bevacizumab vs. 0.9% saline intraperitoneally was evaluated on Right ventricular pressure (RVP) (p=0.01). Bevacizumab significantly reduced median right ventricular pressure (32.3 mmHg vs 37.8 mmHg, p=0.01) compared to saline in rats with hypoxia-induced pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: